How to access Alecensa from Saudi Arabia — the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
A Saudi patient newly diagnosed with ALK-positive non-small-cell lung cancer (NSCLC) may receive a prescription for Alecensa (alectinib) from their treating medical oncologist, typically as first-line therapy following confirmation of an ALK rearrangement. Alecensa is FDA-approved in the United States and is a widely used first-line option for ALK-positive advanced NSCLC, including in patients with CNS metastases. In the Kingdom of Saudi Arabia, Alecensa may not always be routinely stocked across all tertiary oncology pharmacies, which is why your oncologist may be coordinating a named-patient import pathway on your behalf.
This guide explains the legal pathway, what documentation your physician needs, typical timing and cost bands, and where Reserve Meds fits in.
The clinical situation
Alecensa is a second-generation oral ALK tyrosine kinase inhibitor with strong CNS penetration. Eligibility requires molecular confirmation of an ALK rearrangement from tumour tissue or liquid biopsy. The manufacturer is Genentech / Roche. Dosing is typically 600 mg orally twice daily with food as continuous therapy, with monitoring for liver enzymes, bradycardia, myalgia, and photosensitivity. Your oncologist will confirm ALK status and sequencing against your overall treatment plan.
Is Alecensa legally importable into Saudi Arabia?
Yes — through the Saudi Food and Drug Authority (SFDA) named-patient import framework. Saudi Arabia has a mature named-patient mechanism that has supported cross-border access to specialised oncology products for many years.
The SFDA named-patient route allows a Saudi-licensed physician to request import of a medicine that is not locally registered when: (a) the medicine has been approved by a recognised reference authority (FDA qualifies), (b) there is no clinically equivalent locally registered alternative, (c) the treating physician takes clinical responsibility for use, and (d) the importing party documents chain of custody from the US source to the administering facility. Applications are reviewed by the SFDA Drug Sector and are typically filed by the hospital's importing pharmacy on the physician's behalf.
How the pathway works, step by step
- Consultation with your treating oncologist. The decision to prescribe Alecensa is a clinical one. Your oncologist will document ALK status and treatment rationale.
- Administering facility identification. A Saudi tertiary oncology centre with an importing pharmacy files on behalf of the physician. Several centres in Riyadh, Jeddah, and the Eastern Province routinely handle named-patient imports.
- SFDA named-patient application. Your physician or the hospital's importing pharmacy files an application with SFDA including clinical rationale, patient identifier, product details, and chain-of-custody plan.
- US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure product from the manufacturer's authorised distribution chain under DSCSA.
- Temperature-controlled shipment. Alecensa is a stable oral capsule; shipments travel with tamper-evident packaging and end-to-end documentation.
- Arrival and dispensing support. Your oncologist remains the treating clinician. Reserve Meds coordinates re-supply ahead of cycle end to avoid treatment gaps.
What documentation your physician needs
Your physician will typically need to provide:
- A clinical rationale letter confirming ALK status, prior therapies (if any), and Alecensa as the indicated treatment
- Verification of their Saudi medical licence (SCFHS / MOH)
- A current prescription naming the product, strength, and quantity
- Patient identifier (anonymised reference preferred)
- The planned treatment cadence (continuous daily therapy with monthly re-supply)
Reserve Meds provides a physician documentation kit that bundles the templates SFDA reviewers expect to see for oncology oral therapies under named-patient import.
Costs and timing
Alecensa's US cash-pay reference price for a 30-day supply sits in an indicative 2026 range of roughly USD 17,000–20,000. Logistics, SFDA documentation handling, and concierge coordination add incremental cost; Reserve Meds issues a full transparent quote at the start of intake.
Indicative timing — not guaranteed — for first shipment arrival after cohort intake opens is approximately 14–28 days from the moment a complete SFDA application is submitted. Subsequent re-supply cycles are generally faster once the pathway is established.
Reserve Meds is in pre-launch. Fulfillment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, flag that when you join the waitlist — we triage accordingly.
A brief culturally-aware note: Ramadan and Hajj seasons can affect scheduling across Saudi tertiary centres. Our concierge team coordinates re-supply timing with your family's preferences and your hospital's calendar.
Reserve Meds's role
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For Alecensa specifically, we provide:
- Sourcing. Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody.
- Documentation. Regulatory documentation package for your physician and for SFDA review.
- Logistics. Temperature-stable shipment and chain-of-custody coordination.
- Concierge case lead. A named point of contact for your family and your physician throughout the process.
What we do not do: we are not the prescriber, we do not practise medicine, and we are not the dispensing pharmacy. All clinical decisions remain with your treating oncologist. We operate on a waitlist basis during our pre-launch phase.
Frequently asked
Is this legal in Saudi Arabia? Yes, when executed through the SFDA named-patient framework with appropriate documentation. The pathway has been used routinely across oncology for many years. See our trust and compliance page.
What if my oncologist has not done this before? Named-patient import is an institutional process your oncologist's hospital will have encountered, even if the individual physician has not. Our documentation kit closes the gap for first-time applicants.
Does Alecensa work on CNS metastases? Alecensa has documented CNS activity; your oncologist will discuss expected benefit for your specific disease pattern.
Will private insurance cover this? Cash-pay is the default. Some Saudi private insurers reimburse named-patient imports on case-by-case approval; we supply documentation for your submission but do not process insurance claims directly.
Next step — join the first-cohort waitlist
Reserve Meds is opening to a limited first cohort in 2026. Add your case to the waitlist and our concierge case lead will reach out when we are ready to enter intake for Alecensa coordination in Saudi Arabia.
Add me to the Alecensa waitlist> Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.
Clinical & regulatory review: Reserve Meds clinical team and AI regulatory-counsel review pipeline. Last medically reviewed: 2026-04-23.